Enhancement of human eosinophil apoptosis by fluticasone propionate, budesonide, and beclomethasone
Authors:
- Eeva MoilanenEMEeva Moilanen
- Hannu KankaanrantaHKHannu Kankaanranta
- 1 October 2000
- journal article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 406 (3) , 325-332
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Apoptosis of eosinophils and lymphocytes in allergic inflammationJournal of Allergy and Clinical Immunology, 1999
- Adrenal Effects and Pharmacokinetics of CFC-free Beclomethasone Dipropionate: a 14-Day Dose-Response StudyJournal of Pharmacy and Pharmacology, 1999
- Inhibition of interleukin‐5 mediated eosinophil viability by fluticasone 17‐propionate: comparison with other glucocorticoidsClinical & Experimental Allergy, 1998
- A comparison of the efficacy and safety of inhaled corticosteroids in asthmaAllergy, 1997
- Resolution of chronic inflammation by therapeutic induction of apoptosisTrends in Pharmacological Sciences, 1996
- Eosinophil apoptosis caused by theophylline, glucocorticoids, and macrolides after stimulation with IL-5Journal of Allergy and Clinical Immunology, 1996
- Dissection of TNF Receptor 1 Effector Functions: JNK Activation Is Not Linked to Apoptosis While NF-κB Activation Prevents Cell DeathCell, 1996
- Pathophysiology of asthmaBritish Journal of Clinical Pharmacology, 1996
- Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDIEuropean Respiratory Journal, 1994
- Effects of IL-5, granulocyte/macrophage colony-stimulating factor (GM-CSF) and IL-3 on the survival of human blood eosinophilsin vitroClinical and Experimental Immunology, 1991